Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?

Schizophrenia Bulletin

Volumn 39, Issue 5, 2013, Pages 962-965

  Harrow, Martin ^a   Jobe, Thomas H ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

longitudinal studies; outcome; psychosis; unmedicated patients

Indexed keywords

DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; CANADA; DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE; REMISSION; SCHIZOPHRENIA; SHORT COURSE THERAPY; SUPERSENSITIVITY; UNITED STATES;

LONGITUDINAL STUDIES; OUTCOME; PSYCHOSIS; UNMEDICATED PATIENTS;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883477842     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt034     Document Type: Article

References (27)

1. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52:173-188
2. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564
3. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56
4. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100:20-38
5. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A 15-year multifollow-up study. J Nerv Ment Dis. 2007;195:406-414
6. Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med. 2012;42:2145-2155
7. Jobe T, Harrow M. Schizophrenia course, long-term outcome, recovery, and prognosis. Curr Dir Psychol Sci. 2010;19:220-225
8. Silverstein SM, Bellack AS. A scientific agenda for the concept of recovery as it applies to schizophrenia. Clin Psychol Rev. 2008;28:1108-1124
9. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449
10. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54:49-55
11. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114:3-13
12. Jablensky A, Sartorius N. What did the WHO studies really find? Schizophr Bull. 2008;34:253-255
13. Tranter R, Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol. 1998;12:401-406
14. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. 'Breakthrough' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979-2986
15. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;5:CD008016
16. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet. 2012;379:2063-2071
17. Harrow M, Grossman LS, Jobe TH, Herbener ES. Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr Bull. 2005;31:723-734
18. Ventura J, Subotnik KL, Guzik LH, et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res. 2011;132:18-23
19. Carpenter WT Jr, Stephens JH. Prognosis as the critical variable in classification of the functional psychoses. J Nerv Ment Dis. 1982;170:688-691
20. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 1987;144:727-735
21. Harding CM, Zahniser JH. Empirical correction of seven myths about schizophrenia with implications for treatment. Acta Psychiatr Scand Suppl. 1994;384:140-146
22. Fenton WS, McGlashan TH. Sustained remission in drugfree schizophrenic patients. Am J Psychiatry. 1987;144: 1306-1309
23. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry. 1994;151: 1409-1416
24. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia [published online ahead of print November 20, 2012]. Schizophr Bull. doi:10.1093/schbul/sbs130
25. Whitaker R. Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. New York, NY: Broadway Books; 2011
26. Whitaker R. Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill. New York, NY: Basic Books; 2010
27. Moncrieff J. The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment. Basingstoke, UK: Palgrave Macmillan; 2009